格列美脲与二甲双胍对2型糖尿病患者血管内膜纤溶酶原活性的影响
 |
| 第1页 |
参见附件。
[摘要]目的 研究分析格列美脲与二甲双胍对于2型糖尿病患者血管内膜纤溶酶原活性的影响。方法 选择我院从2010年10月到2013年10月收治的100例2型糖尿病患者，将所有患者随机分为观察组和对照组两组，每组各50例。观察组给予格列美脲治疗，对照组患者给予二甲双胍进行治疗。对比两组患者治疗后组织型纤溶酶原激活剂(T-PA)以及纤溶酶原激活剂抑制物(PAI-1)的浓度变化情况。结果 治疗后，两组患者FPG、HbAlc、HOMA-胰岛素抵抗、PAI-1等指标明显下降，T-PA上升，但观察组较对照组上述指标改善更加显著，组间对比差异有统计学意义(P<0.05)。结论 对于2型糖尿病患者采用格列美脲具有比较好的治疗效果，能够有效控制患者血糖，改善纤溶活性，值得广泛运用。
[Abstract] Objective To study the effect of glimepiride and metformin for analysis of plasmin endometrial blood vessels in patients with type 2 diabetes mellitus primary activity. Methods in our hospital from 2010 October to 2013 October were treated 100 cases of type 2 diabetic patients, all patients were randomly divided into observation group and control group two groups, 50 patients in each group. The observation group was given glimepiride treatment, the control group were treated with metformin. Comparing the two groups of patients after treatment of tissue type plasminogen activator (T-PA) and plasminogen activator inhibitor (PAI-1) concentration ......
您现在查看是摘要介绍页，详见PDF附件。